April 12, 2017 / 9:40 PM / 2 years ago

Federal Circuit rules Novartis multiple sclerosis drug patent invalid

In a win for three generic drugmakers, a federal appeals court on Wednesday held that Novartis’ patent on the blockbuster multiple sclerosis drug Gilenya was invalid.

A unanimous panel of the U.S. Circuit Court of Appeals for the Federal Circuit affirmed a 2015 ruling by the U.S. Patent Trial and Appeal Board (PTAB), which agreed with generic drugmakers Torrent Pharmaceuticals, Apotex and Mylan Pharmaceuticals that the Gilenya patent was obvious based on a combination of prior innovations.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/2opFJFV

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below